Blue Cross Blue Shield Oklahoma policy
Management of Hereditary Angioedema (HAE) with C1 Esterase Inhibitor, Human and Ecallantide
Management of Hereditary Angioedema (HAE) with C1 Esterase Inhibitor, Human and Ecallantide is a public Blue Cross Blue Shield Oklahoma policy (policy RX504.013, effective Jan 1, 2026). It lists 2 CPT or HCPCS codes. Not a coverage decision; the payer's own document governs.
View the original policy (PDF) ↗
Check eligibility for free
No account required. Sign a BAA to see plan details, coordination of benefits and more
- Policy number
- RX504.013
- Effective
- Jan 1, 2026
- Line of business
- Commercial, Medicaid
- Source
- medicalpolicy.hcsc.com
Codes in this policy
The CPT and HCPCS codes the policy names. A policy can name a code it excludes. Open official prior authorization lists to check the member’s product.
| Code | Other Blue Cross Blue Shield Oklahoma policies |
|---|---|
| J0598 | Policies naming J0598 |
| J1290 | Policies naming J1290 |
All Blue Cross Blue Shield Oklahoma policies · Blue Cross Blue Shield Oklahoma prior authorization CPT list